$56M Series B funding was provided to SwanBio Therapeutics, a Philadelphia-based gene therapy company called.
Syncona Limited and Mass General Brigham Ventures led the round. It brings the total amount of financing raised to date to $133 million.
The company plans to use the funds to continue its evolution into a fully integrated, research and development organization. It will initially focus on the clinical advancement of SBT101. This includes plans to do patients in Phase 1/2 trials by the end of this year. Further progress will be made to the pipeline to apply the learnings from SBT101 and other monogenic disorders as well as to further develop the pipeline.
SwanBio Therapeutics, a gene therapy company, aims to provide life-changing treatments for people with inherited neurological disorders. The company is developing a pipeline for gene therapies that can be administered intrathecally and which can target both the central as well as peripheral nervous systems. This approach has the potential to be applied broadly across three disease classifications – spastic paraplegias, monogenic neuropathies, and polygenic neuropathies. Its lead program is being advanced toward clinical development for the treatment of adrenomyeloneuropathy (AMN).
SBT101 is the first clinical-stage AAV-based gene therapy candidate for the treatment of adrenomyeloneuropathy (AMN). The drug’s investigational purpose is to correct the disease-causing symptoms. ABCD1AMN patients are more likely to have mutations. This mutation affects the function and structure of spinal cord cells and other tissues. It can lead to nerve degeneration that causes loss of mobility, incontinence, debilitating and sexual dysfunction, as well as incontinence and debilitating pain. As well as adrenal gland dysfunction, patients often suffer from this condition. In early 2022, the FDA cleared SwanBio’s Investigational New Drug application for SBT101 and granted Orphan Drug and Fast Track designations to SBT101. SwanBio has begun to develop a pipeline for gene therapy candidates that can be administered intrathecally to target organs in the central and peripheral nervous system. The initial focus is on AMN and spinal cord-related disorders.